This review addresses the rationale and evidence for-and the challenges, cost implications, and future development of-proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.
Stella Flampouri, PhD
Advertisement
Articles by Stella Flampouri, PhD
Advertisement
Latest Updated Articles
Improving the Therapeutic Ratio in Hodgkin Lymphoma Through the Use of Proton TherapyPublished: May 15th 2012 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
3
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
4
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
5
